Cathal Roarty1, Claire Tonry1, Lisa McFetridge2, Hannah Mitchell2, Chris Watson1, Thomas Waterfield3. 1. Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT97BL, UK. 2. Mathematical Sciences Research Centre, Queen's University Belfast, Belfast BT97BL, UK. 3. Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT97BL, UK; Children's Health Ireland at Temple Street, Dublin, Ireland. Electronic address: t.waterfield@qub.ac.uk.
To the best of our knowledge, no longitudinal study has reported the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in children. Here we report the results of the second round of antibody testing in children from a prospective multicentre cohort study in the UK. The protocol and initial results are available elsewhere.1, 2 Recruitment took place between April 16, and July 3, 2020, at five UK sites (Belfast, Cardiff, Glasgow, London, and Manchester) and included healthy children aged 2–15 years. Follow-up visits at all five UK sites took place between June 26, and Aug 15, 2020.Of the 992 participants in the first round, 849 (86%) returned. Seroprevalence was measured with the Elecsys Anti-SARS-CoV-2 Total Antibody assay (Roche, Basel, Switzerland) and the LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy). The median time between initial and follow-up visits was 62 days (IQR 52–70; range 43–81). 65 (7·66%, 95% CI 6·05–9·64) of 849 tests were reactive based on the manufacturers' suggested cutoffs. This proportion was not substantially different to the seroprevalence (6·9% 95% CI 5·4 to 8·6; 68 of 992) reported during recruitment. The median age of participants with reactive antibody tests during the second round was 10 years (IQR 7–14; range 3–16). As with the baseline results, there was variation in seroprevalence between sites (appendix p 3).45 participants with reactive antibody tests in the first round who attended the follow-up visit had reactive antibody tests in the second round. In these individuals, we observed increases in antibody titres from the first round to the second round with both assays: with Roche's Elecsys assay, mean antibody titres increased from 84·7 cutoff index (COI) to 115·8 COI (difference 31·08, 95% CI 13·82–48·34, p=0·0007), and with DiaSorin's LIAISON assay, mean antibody titres increased from 67·5 AU/mL to 81·4 AU/mL (13·89, 0·31–27·46; p=0·0452).These results indicate that antibody titres in children exposed to SARS-CoV-2 remain at a detectable level for at least 62 days, and that in this cohort mean antibody titres increased over time. This finding is consistent with available data on antibody titres in adults.3, 4
Authors: Georgina Ireland; Anna Jeffery-Smith; Maria Zambon; Katja Hoschler; Ross Harris; John Poh; Frances Baawuah; Joanne Beckmann; Ifeanyichukwu O Okike; Shazaad Ahmad; Joanna Garstang; Andrew J Brent; Bernadette Brent; Felicity Aiano; Zahin Amin-Chowdhury; Louise Letley; Samuel E I Jones; Meaghan Kall; Monika Patel; Robin Gopal; Ray Borrow; Ezra Linley; Gayatri Amirthalingam; Kevin E Brown; Mary E Ramsay; Shamez N Ladhani Journal: EClinicalMedicine Date: 2021-09-30
Authors: Carolin Kirsten; Elisabeth Kahre; Judith Blankenburg; Leonie Schumm; Luise Haag; Lukas Galow; Manja Unrath; Paula Czyborra; Josephine Schneider; Christian Lück; Alexander H Dalpke; Reinhard Berner; Jakob Armann Journal: Infection Date: 2022-04-23 Impact factor: 7.455
Authors: Karen Cortés-Sarabia; Armando Cruz-Rangel; Alejandro Flores-Alanis; Marcela Salazar-García; Samuel Jiménez-García; Griselda Rodríguez-Martínez; Juan Pablo Reyes-Grajeda; Rosa Isela Rodríguez-Téllez; Genaro Patiño-López; Israel Parra-Ortega; Oscar Del Moral-Hernández; Berenice Illades-Aguiar; Miguel Klünder-Klünder; Horacio Márquez-González; Adrián Chávez-López; Victor M Luna-Pineda Journal: PLoS One Date: 2022-08-15 Impact factor: 3.752
Authors: Kevin Paul; Freya Sibbertsen; Daniela Weiskopf; Marc Lütgehetmann; Madalena Barroso; Marta K Danecka; Laura Glau; Laura Hecher; Katharina Hermann; Aloisa Kohl; Jun Oh; Julian Schulze Zur Wiesch; Alessandro Sette; Eva Tolosa; Eik Vettorazzi; Mathias Woidy; Antonia Zapf; Dimitra E Zazara; Thomas S Mir; Ania C Muntau; Søren W Gersting; Gabor A Dunay Journal: Front Immunol Date: 2022-07-15 Impact factor: 8.786
Authors: Jakob Peter Armann; Carolin Kirsten; Lukas Galow; Elisabeth Kahre; Luise Haag; Alexander Dalpke; Christian Lück; Reinhard Berner Journal: BMJ Paediatr Open Date: 2021-03-24
Authors: Antoine N Nkuba; Sheila M Makiala; Emilande Guichet; Paul M Tshiminyi; Yannick M Bazitama; Marc K Yambayamba; Benito M Kazenza; Trésor M Kabeya; Elysee B Matungulu; Lionel K Baketana; Naomi M Mitongo; Guillaume Thaurignac; Fabian H Leendertz; Veerle Vanlerberghe; Raphaël Pelloquin; Jean-François Etard; David Maman; Placide K Mbala; Ahidjo Ayouba; Martine Peeters; Jean-Jacques T Muyembe; Eric Delaporte; Steve M Ahuka Journal: Clin Infect Dis Date: 2022-03-09 Impact factor: 9.079
Authors: Lauren E Gentles; Leanne Kehoe; Katharine H D Crawford; Kirsten Lacombe; Jane Dickerson; Caitlin Wolf; Joanna Yuan; Susanna Schuler; John T Watson; Sankan Nyanseor; Melissa Briggs-Hagen; Sharon Saydah; Claire M Midgley; Kimberly Pringle; Helen Chu; Jesse D Bloom; Janet A Englund Journal: medRxiv Date: 2022-01-25